Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC10914 Monotherapy in BRCA-mutated mCRPC
NCT04486937Phase 2Unknown
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Aug 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of SC10914 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Status: unknown.
02
Drugs
SC10914
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04486937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486937.